By Fineline Cube 
China-based Contract Research Organization (CRO) Viva Biotech (HKG: 1873) announced that its wholly-owned subsidiary, Hangzhou Viva Zongchen, will collaborate to establish an RMB 300 million fund with Nanjing Ruihong, Nanjing High-Quality, Nanjing BPV, Nanjing Yangzi, Nanjing Beilian, Nanjing New Town, Nanjing Gaoxin, Shanghai Hongene, BrightGene Bio-Medical, and Jiangsu Dingtai. Hangzhou Viva Zongchen has committed RMB 25 million, representing 8.3% of the fund.
Fund Details
The fund, set to run for seven years, will concentrate on early-stage pharmaceutical discovery and development projects. It will prioritize cutting-edge technological innovations and their translation in the life sciences sector. This initiative underscores Viva Biotech’s commitment to fostering innovation and supporting the growth of emerging pharmaceutical technologies.-Fineline Info & Tech